Obstructive Sleep Apnea-OSA

Managing Mask-Related Side Effects: A Key to CPAP Therapy Adherence

By

Tori Rodriguez, MA, LPC, AHC

Mask-related side effects have been cited as the most important factor influencing adherence to continuous positive airway pressure (CPAP) therapy.

Obstructive Sleep Apnea as a Potential Risk Factor for COVID-19: Expert Interview

By

Tori Rodriguez, MA, LPC, AHC

Obstructive sleep apnea may represent another important variable contributing to increased risk related to COVID-19.

The Relationship Between OSA and Mood Disorders, Cognitive Impairment

By

Tori Rodriguez, MA, LPC, AHC

Common comorbidities in OSA such as cardiovascular disease and metabolic abnormalities, may confer a higher risk for the development of mental and cognitive impairment in patients with OSA compared with the general population.

Patients With Ankylosing Spondylitis Do Not Have Higher Prevalence of Obstructive Sleep Apnea

By

Sheila Jacobs

Researchers assessed the prevalence of obstructive sleep apnea in patients with ankylosing spondylitis compared with matched control participants, and determined factors associated with OSA in patients with AS.

Clinical Trial Findings for Belun Wearable Ring Technology for OSA Detection

By

Sheila Jacobs

A clinical trial examined the validity of the Belun Sleep Platform (BSP) wearable ring technology, a home sleep apnea detection system using a neural network algorithm.

Links Between OSA and White Matter Hyperintensities Common in Brain Aging

By

Bryant Moeller

Researchers explored the relationship between OSA and white matter hyperintensities, which are associated with brain aging and dementia.

Study Explores the Relationship Between COVID-19 Outcomes and OSA

By

Sheila Jacobs

Do patients with COVID-19 and obstructive sleep apnea have a worse prognosis than those without OSA?

SANDMAN trial finds BAY 2253651 Not Effective for Obstructive Sleep Apnea

By

Virginia A. Schad, PharmD, RPh

What did the SANDMAN trial find — and could a chemically altered follow-up to BAY 2253651 fill the void of pharmacological agents for treating OSA?